IMGT (XKRX:456570) Total Long-Term Assets : ₩2,134.61 Mil (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is IMGT Total Long-Term Assets?

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. IMGT's Total Long-Term Assets for the quarter that ended in Dec. 2023 was ₩2,134.61 Mil.

IMGT Total Long-Term Assets Historical Data

The historical data trend for IMGT's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IMGT Total Long-Term Assets Chart

IMGT Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Total Long-Term Assets

1,960.35

3,246.52

2,544.87

2,134.61

IMGT Semi-Annual Data
	Dec20	Dec21	Dec22	Dec23
Total Long-Term Assets	1,960.35	3,246.52	2,544.87	2,134.61

IMGT Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.

IMGT Total Long-Term Assets Related Terms

Thank you for viewing the detailed overview of IMGT's Total Long-Term Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

IMGT Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IMGT Corp Ltd (XKRX:456570) » Definitions » Total Long-Term Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

172 Dolma-ro,, 408, Healthcare Innovation Park, Bundang-gu, Gyeonggi-do, Seongnam-si, KOR, 13605

Website

http://www.imgt.co.kr

IMGT Corp Ltd develops a focused ultrasound-based drug delivery platform for intractable diseases. It is developing nanomedicines and focused ultrasound medical devices that respond to focused ultrasound. The firm has two pipeline products IMD20 and IMP101. IMD20 is a FUS device developed for chronic pain as a product with reduced size and output from IMD10 developed for cancer treatment. IMP101 is a nanoparticle used for hepatocarcinoma embolization.

IMGT Headlines

No Headlines